Norman Coleman, Gay Crawford to receive NCCS Stovall Award for advancing patient-centered care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Norman Coleman, associate director of NCI’s Radiation Research Program and Gay Crawford, founding director of Cancer CAREpoint, were named recipients of the National Coalition for Cancer Survivorship’s Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care.

Named for longtime CEO of NCCS and three-time cancer survivor Ellen Stovall, who died in 2016, the award aims to honor her memory and advocacy by annually recognizing individuals, organizations, or other entities that are innovators in improving cancer care.

Coleman has been affiliated with NCCS since working with Stovall on the NCAB/Senate Subcommittee to Evaluate the National Cancer Program in 1993. He helped form the New England Coalition for Cancer Survivorship while at Harvard. He is senior scientific advisor to the International Cancer Expert Corps, a non-government organization focusing on global disparities in cancer care.

Crawford has counseled thousands of patients and families over the past 44 years. Some of the programs she helped found include: Hospice of the Valley, the second non-profit hospice in California; Courageous Kids, an American Cancer Society program for children with cancer; the California Cancer Registry; the Colon Cancer Free Zone, advocating for colon cancer screening; and was successful in lobbying the insurance industry to pay for breast reconstructions for patients.

In 2011, she was invited to serve as the first chair of Stanford’s new South Bay Cancer Center Patient and Family Advisory Council, helping to develop the program and keep the focus on patient-focused care. In 2013, Crawford founded Cancer CAREpoint, a Silicon Valley based nonprofit organization.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login